` AFMD (Affimed NV) vs S&P 500 Comparison - Alpha Spread

AFMD
vs
S&P 500

Over the past 12 months, AFMD has underperformed S&P 500, delivering a return of -96% compared to the S&P 500's 12% growth.

Stocks Performance
AFMD vs S&P 500

Loading
AFMD
S&P 500
Add Stock

Performance Gap
AFMD vs S&P 500

Loading
AFMD
S&P 500
Difference

Performance By Year
AFMD vs S&P 500

Loading
AFMD
S&P 500
Add Stock

Competitors Performance
Affimed NV vs Peers

S&P 500
AFMD
ABBV
AMGN
GILD
VRTX
Add Stock

Affimed NV
Glance View

Market Cap
3.1m USD
Industry
Biotechnology

Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

AFMD Intrinsic Value
Not Available
Back to Top